199 related articles for article (PubMed ID: 16757169)
1. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
[TBL] [Abstract][Full Text] [Related]
2. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
4. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
[TBL] [Abstract][Full Text] [Related]
5. Disubstituted pyrimidines as Lck inhibitors.
Hunt JA; Beresis RT; Goulet JL; Holmes MA; Hong XJ; Kovacs E; Mills SG; Ruzek RD; Wong F; Hermes JD; Park YW; Salowe SP; Sonatore LM; Wu L; Woods A; Zaller DM; Sinclair PJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5440-3. PubMed ID: 19674899
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
7. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
[TBL] [Abstract][Full Text] [Related]
8. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
[TBL] [Abstract][Full Text] [Related]
9. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
[TBL] [Abstract][Full Text] [Related]
10. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
[TBL] [Abstract][Full Text] [Related]
11. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
13. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
[TBL] [Abstract][Full Text] [Related]
14. SVM model for virtual screening of Lck inhibitors.
Liew CY; Ma XH; Liu X; Yap CW
J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
[TBL] [Abstract][Full Text] [Related]
15. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Koami T; Shiozawa F; Oka Y; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):112-6. PubMed ID: 19945867
[TBL] [Abstract][Full Text] [Related]
16. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
Burchat A; Borhani DW; Calderwood DJ; Hirst GC; Li B; Stachlewitz RF
Bioorg Med Chem Lett; 2006 Jan; 16(1):118-22. PubMed ID: 16216497
[TBL] [Abstract][Full Text] [Related]
17. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
[TBL] [Abstract][Full Text] [Related]
19. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
[TBL] [Abstract][Full Text] [Related]
20. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
Li J; Du J; Xi L; Liu H; Yao X; Liu M
Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
